Abeona Therapeutics Inc.

Good day ladies and gentlemen and welcome to the Abiona Therapeutics first quarter 2026 earnings conference call. At this time all participants are on a listen only mode and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. And please note, this conference is being recorded. I will now turn the conference over to your host, Mr. Joe Vizzano, Chief Financial Officer at Abiona Therapeutics. Sir, the floor is yours.

Thank you, Operator. Good morning, and thank you for joining us on our first quarter 2026 Results and Business Update conference calls. During this call, we will refer to the press release issued this morning announcing the financial results, which is available on our corporate website at www.abionatherapeutics.com. We anticipate making projections and forward-looking statements during today's call, which are made pursuant to the safe harbor provisions of the Federal Securities Law. These forward-looking statements are based on current expectations and are subject to change. Actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including but not limited to those outlined in our Form 10-K and periodic reports filed with the Securities and Exchange Commission. These documents are available on our website at www.aviantherapeutics.com. Joining me on today's call with prepared remarks are Dr. Vishesh Chaudhry, Chief Executive Officer, and Dr. Madhav Basantabhata, Chief Commercial Officer. With that, I will now turn the call over to Dr. Shashadri to kick us off.

Thank you, Joe, and good morning, everyone. First, we are excited to share updates on leading indicators of ZivaScan adoption that signal strong momentum since treating our first commercial patient in December. We have now activated six Qualified Treatment Centers, or QTCs, treated our fifth commercial patient with manufacturing underway for the sixth, and schedule additional patients throughout the current quarter. The recent acceleration of onboarding efforts of QTCs further underscores their conviction about the role that ZivaSkin will play in addressing the unmet needs of patients suffering from recessive dystrophic epidermolysis bullosa, or RDEV. Three of the ZivaSkin treatments reported to date took place in Q1, 2026, and translated into net revenue of $8.7 million for that quarter. Second, we're sharing meaningful updates to our R&D pipeline, featuring a potentially game-changing, radically novel engineered T-cell technology for advanced prostate cancer. By leveraging our proven expertise in advancing complex cell and gene therapies from academia through commercialization, we are well-positioned to advance this exciting technology. But before going there, I'll first turn the call over to Dr. Madhav Basantavada, to elaborate on the ZivaSkin launch, which is our foundational and primary focus for Aviona. Madhav?